Literature DB >> 7539151

Identification of the causative agent of granulocytic ehrlichiosis in Swedish dogs and horses by direct solid phase sequencing of PCR products from the 16S rRNA gene.

K E Johansson1, B Pettersson, M Uhlén, A Gunnarsson, M Malmqvist, E Olsson.   

Abstract

Seven Swedish isolates of Ehrlichia species from the blood of four dogs and three horses with clinical granulocytic ehrlichiosis, were identified by direct solid phase DNA sequencing of polymerase chain reaction (PCR) products from the 16S rRNA gene. The amplified DNA fragments were produced with primers complementary to the universal regions, U1, U2, U5 and U8 of the 16S rRNA molecule. Identical sequences were obtained from all seven isolates. This nucleotide sequence was similar to the sequences deposited in GenBank for Ehrlichia phagocytophila and E equi. The sequence of the Swedish ehrlichiae differed in two nucleotide positions from the E phagocytophila sequence and in three positions from the E equi sequence, and it is tentatively proposed that it is a subspecies of one of these two. The alignment of the sequence of the Swedish isolates with a recently deposited sequence from human cases of ehrlichiosis in the USA revealed 100 per cent identity in a segment of about 1400 bp.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7539151     DOI: 10.1016/0034-5288(95)90061-6

Source DB:  PubMed          Journal:  Res Vet Sci        ISSN: 0034-5288            Impact factor:   2.534


  35 in total

1.  Granulocytic ehrlichiosis in two dogs in Switzerland.

Authors:  N Pusterla; J Huder; C Wolfensberger; B Litschi; A Parvis; H Lutz
Journal:  J Clin Microbiol       Date:  1997-09       Impact factor: 5.948

2.  Polymorphism and transcription at the p44-1/p44-18 genomic locus in Anaplasma phagocytophilum strains from diverse geographic regions.

Authors:  Quan Lin; Yasuko Rikihisa; Robert F Massung; Zerai Woldehiwet; Richard C Falco
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

3.  Isolation of the equine granulocytic ehrlichiosis agent, Ehrlichia equi, in tick cell culture.

Authors:  U G Munderloh; J E Madigan; J S Dumler; J L Goodman; S F Hayes; J E Barlough; C M Nelson; T J Kurtti
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

4.  Propagation of granulocytic Ehrlichia spp. from human and equine sources in HL-60 cells induced to differentiate into functional granulocytes.

Authors:  R Heimer; A Van Andel; G P Wormser; M L Wilson
Journal:  J Clin Microbiol       Date:  1997-04       Impact factor: 5.948

5.  Isolation of Actinobaculum schaalii and Actinobaculum urinale from a patient with chronic renal failure.

Authors:  Faiz Fendukly; Björn Osterman
Journal:  J Clin Microbiol       Date:  2005-07       Impact factor: 5.948

6.  The agent of Human Granulocytic Ehrlichiosis resides in an endosomal compartment.

Authors:  P Webster; J W IJdo; L M Chicoine; E Fikrig
Journal:  J Clin Invest       Date:  1998-05-01       Impact factor: 14.808

7.  Evidence of the human granulocytic ehrlichiosis agent in Ixodes ricinus ticks in Switzerland.

Authors:  N Pusterla; C M Leutenegger; J B Huder; R Weber; U Braun; H Lutz
Journal:  J Clin Microbiol       Date:  1999-05       Impact factor: 5.948

8.  Characterization of a spotted fever group Rickettsia from Ixodes ricinus ticks in Sweden.

Authors:  K Nilsson; T G Jaenson; I Uhnoo; O Lindquist; B Pettersson; M Uhlén; G Friman; C Påhlson
Journal:  J Clin Microbiol       Date:  1997-01       Impact factor: 5.948

9.  Sequential evaluation of dogs naturally infected with Ehrlichia canis, Ehrlichia chaffeensis, Ehrlichia equi, Ehrlichia ewingii, or Bartonella vinsonii.

Authors:  E B Breitschwerdt; B C Hegarty; S I Hancock
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

10.  Protection against Ehrlichia equi is conferred by prior infection with the human granulocytotropic Ehrlichia (HGE agent).

Authors:  J E Barlough; J E Madigan; E DeRock; J S Dumler; J S Bakken
Journal:  J Clin Microbiol       Date:  1995-12       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.